Key result
Combined chymase and ACE inhibition, relative to ACE inhibition alone, improved left ventricular function, decreased adverse cardiac remodeling, and improved survival after myocardial infarction in hamsters.
Why the study?
Does combined chymase and ACE inhibition improve cardiac remodeling and function compared to ACE inhibition alone in rodent models of myocardial infarction?
Does combined chymase and ACE inhibition improve cardiac remodeling and function compared to ACE inhibition alone in rodent models of myocardial infarction?
Mast cell chymase release during ACE inhibition maintains cardiac Ang II levels, and adding a chymase inhibitor to ACE inhibitor therapy improves post-MI cardiac remodeling and survival in rodents.
Answers are grounded in this paper and cite their sources.
Does not yet alter post-MI therapy; extends rodent evidence for combined chymase-ACE inhibition.
Ang I-converting enzyme (ACE) inhibitors are widely believed to suppress the deleterious cardiac effects of Ang II by inhibiting locally generated Ang II. However, the recent demonstration that chymase, an Ang II-forming enzyme stored in mast cell granules, is present in the heart has added uncertainty to this view. As discussed here, using microdialysis probes tethered to the heart of conscious mice, we have shown that chronic ACE inhibitor treatment did not suppress Ang II levels in the LV interstitial fluid (ISF) despite marked inhibition of ACE. However, chronic ACE inhibition caused a marked bradykinin/B2 receptor-mediated increase in LV ISF chymase activity that was not observed in mast cell-deficient KitW/KitW-v mice. In chronic ACE inhibitor-treated mast cell-sufficient littermates, chymase inhibition decreased LV ISF Ang II levels substantially, indicating the importance of mast cell chymase in regulating cardiac Ang II levels. Chymase-dependent processing of other regulatory peptides also promotes inflammation and tissue remodeling. We found that combined chymase and ACE inhibition, relative to ACE inhibition alone, improved LV function, decreased adverse cardiac remodeling, and improved survival after myocardial infarction in hamsters. These results suggest that chymase inhibitors could be a useful addition to ACE inhibitor therapy in the treatment of heart failure.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2010) studied Myocardial Infarction and Heart Failure. Combined ACE inhibitor and chymase inhibitor therapy vs. Vehicle or ACE inhibitor monotherapy was evaluated on Left ventricular ejection fraction and infarct area (16% improvement in EF and 51% reduction in infarct area, p=<0.05). Combined chymase and ACE inhibition, relative to ACE inhibition alone, improved left ventricular function, decreased adverse cardiac remodeling, and improved survival after myocardial infarction in hamsters.
Synapse has enriched 10 related papers. Consider them for comparative context: